Actinium Pharmaceuticals Inc. (Delaware)

6.83+1.07+18.58%Vol 1.00M1Y Perf -27.42%
Sep 15th, 2021 16:00 DELAYED
BID6.80 ASK6.84
Open6.16 Previous Close5.76
Pre-Market6.72 After-Market-
 -0.11 -1.61%  - -
Target Price
31.67 
Analyst Rating
Strong Buy 1.00
Potential %
363.69 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     58.34
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
15.11 
Earnings Rating
Buy
Market Cap145.69M 
Earnings Date
22nd Oct 2021
Alpha-0.02 Standard Deviation0.23
Beta1.03 

Today's Price Range

6.016.98

52W Range

5.7013.18

5 Year PE Ratio Range

-1.60-2.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
11.60%
1 Month
13.08%
3 Months
-17.31%
6 Months
-23.86%
1 Year
-27.42%
3 Years
-67.48%
5 Years
-86.45%
10 Years
-

TickerPriceChg.Chg.%
ATNM6.831.070018.58
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.30-0.2516.67
Q01 2021-0.35-0.2917.14
Q03 2019-1.20-1.200.00
Q02 2019--0.90-
Q01 2019-1.80-1.5016.67
Q04 2018-0.06-0.060.00
Q02 2018-0.06-0.0433.33
Q02 2017-0.14-0.1214.29
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.280.00-
12/2021 QR-0.30-3.45Negative
12/2021 FY-1.1222.22Positive
12/2022 FY-1.381.43Positive
Next Report Date22nd Oct 2021
Estimated EPS Next Report-0.28
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.00M
Shares Outstanding21.33M
Shares Float21.32M
Trades Count4.92K
Dollar Volume3.66M
Avg. Volume265.43K
Avg. Weekly Volume333.23K
Avg. Monthly Volume220.73K
Avg. Quarterly Volume181.96K

Actinium Pharmaceuticals Inc. (Delaware) (AMEX: ATNM) stock closed at 6.83 per share at the end of the most recent trading day (a 18.58% change compared to the prior day closing price) with a volume of 1.03M shares and market capitalization of 145.69M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Actinium Pharmaceuticals Inc. (Delaware) CEO is Sandesh Seth.

The one-year performance of Actinium Pharmaceuticals Inc. (Delaware) stock is -27.42%, while year-to-date (YTD) performance is -12.44%. ATNM stock has a five-year performance of -86.45%. Its 52-week range is between 5.7 and 13.18, which gives ATNM stock a 52-week price range ratio of 15.11%

Actinium Pharmaceuticals Inc. (Delaware) currently has a PE ratio of -4.70, a price-to-book (PB) ratio of 1.60, a price-to-sale (PS) ratio of 142.21, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.02%, a ROC of -33.85% and a ROE of -33.21%. The company’s profit margin is -%, its EBITDA margin is -2 478.60%, and its revenue ttm is $888.00 Thousand , which makes it $0.04 revenue per share.

Of the last four earnings reports from Actinium Pharmaceuticals Inc. (Delaware), there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Actinium Pharmaceuticals Inc. (Delaware)’s next earnings report date is 22nd Oct 2021.

The consensus rating of Wall Street analysts for Actinium Pharmaceuticals Inc. (Delaware) is Strong Buy (1), with a target price of $31.67, which is +363.69% compared to the current price. The earnings rating for Actinium Pharmaceuticals Inc. (Delaware) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Actinium Pharmaceuticals Inc. (Delaware) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Actinium Pharmaceuticals Inc. (Delaware) has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.11, ATR14 : 0.34, CCI20 : 269.63, Chaikin Money Flow : -0.02, MACD : -0.11, Money Flow Index : 49.75, ROC : 12.71, RSI : 60.45, STOCH (14,3) : 88.28, STOCH RSI : 1.00, UO : 53.51, Williams %R : -11.72), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Actinium Pharmaceuticals Inc. (Delaware) in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

CEO: Sandesh Seth

Telephone: +1 646 677-3870

Address: 275 Madison Avenue, New York 10016, NY, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

61%39%

Bearish Bullish

57%43%

News

Stocktwits